Bharat Biotech submits data on COVID-19 drug trial in children aged 2-18 years
India is turning its focus towards vaccinating children against coronavirus, having already administered more than 920 million doses to adults.
- Oct 6, 2021,
- Updated Oct 6, 2021 10:26 PM IST
Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India's drug regulator, becoming the country's first company to have tested its shot in very young children.
The South Asian country is turning its focus towards vaccinating children against coronavirus, having already administered more than 920 million doses to adults among its population of nearly 1.4 billion.
India's drug regulator last month allowed vaccine maker Serum Institute to enroll kids aged 7 to 11 years for its trial of U.S. drugmaker Novavax's COVID-19 vaccine.
So far, only drugmaker Zydus Cadila's DNA-based COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged at least 12 years.
Also read: India withdraws from 2022 Birmingham Commonwealth Games, cites Covid concerns
Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India's drug regulator, becoming the country's first company to have tested its shot in very young children.
The South Asian country is turning its focus towards vaccinating children against coronavirus, having already administered more than 920 million doses to adults among its population of nearly 1.4 billion.
India's drug regulator last month allowed vaccine maker Serum Institute to enroll kids aged 7 to 11 years for its trial of U.S. drugmaker Novavax's COVID-19 vaccine.
So far, only drugmaker Zydus Cadila's DNA-based COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged at least 12 years.
Also read: India withdraws from 2022 Birmingham Commonwealth Games, cites Covid concerns